CorMedix IncCRMD
▲ PositiveCapitalDemandrelevance
Q2 revenue and EBITDA beat, raised guidance, and strong cash position.
Impact on stocks 1
Health Care
CorMedix IncCorMedix reported second quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, and reaffirmed full-year revenue guidance of $325 million to $345 million while raising adjusted EBITDA guidance to $125 million to $140 million. The company also announced a multi-year commercial supply agreement for DefenCath with an additional large dialysis organization, bringing commercial supply agreements to all five top U.S. dialysis providers. CorMedix anticipates submission of the sNDA for REZZAYO in prophylaxis in the third quarter, with potential FDA action in the first half of 2027. Second quarter DefenCath sales were $66.1 million, and revenue from the acquired Melinta portfolio was $35.8 million. Net income was $26.0 million, or $0.33 per basic share, and cash and cash equivalents ended the quarter at $256.7 million.
CorMedix IncQ2 revenue and EBITDA beat, raised guidance, and strong cash position.